Wednesday, May 20, 2020 7:16:23 PM
Category: ANTIBODY
Type: PolyTope mAb Therapy™, a defined antibody combination designed to target multiple epitopes and mechanisms of viral evasion, and enabled by IPA’s discovery platforms (including B Cell Select™ and DeepDisplay™) and ImmunoPrecise subsidiary Talem Therapeutics’ access to the transgenic animal platform OmniAb® for direct generation of human antibodies.
Status: IPA said March 30 that its collaboration partner EVQLV submitted its first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against SARS-CoV-2. The sequences were generated in less than one week using computational antibody design, which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
IPA said it will review the antibody candidates, then select approximately 1,200 ideal candidates characterized and screened by EVQLV’s artificial intelligence, and validate the antibody candidates in vitro at IPA’s lab facilities. The companies said they will continue to work on additional panels of computationally generated sequence candidates against SARS-CoV-2.
Earlier last month, IPA announced its PolyTope mAb Therapy approach to developing a COVID-19 treatment. The company also spoke of potentially developing a vaccine for COVID-19, but has not announced any such effort since then.
On February 20, IPA said it designated Ilse Roodink, PhD, chairwoman of Talem’s scientific committee, as its Coronavirus Global Project Leader.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
? FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
? DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
? KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
? TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/
Recent IPA News
- ImmunoPrecise nomme Kristin Taylor au poste de directeur financier • Business Wire • 06/27/2024 10:27:00 PM
- ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer • Business Wire • 06/27/2024 12:01:00 PM
- BioStrand, filiale d’IPA, et PGxAI annoncent un accord de collaboration stratégique visant à développer à l’aide de LENSai™ un modèle d’IA d’avant-garde pour les recommandations pharmacogénomiques • Business Wire • 06/25/2024 11:55:00 PM
- IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ • Business Wire • 06/25/2024 11:02:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 05:01:33 PM
- ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology • Business Wire • 06/12/2024 11:00:00 AM
- BioStrand, filiale d’ImmunoPrecise Antibodies Ltd., reçoit le prestigieux prix Impact 2024 pour sa technologie LENSai™ révolutionnaire • Business Wire • 06/12/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/10/2024 06:23:10 PM
- BioStrand, filiale d’ImmunoPrecise Antibodies, annonce la disponibilité commerciale immédiate de son logiciel révolutionnaire doté d’une interface personnalisable pour la découverte de médicaments optimisée par l’IA • Business Wire • 06/10/2024 03:34:00 PM
- BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery • Business Wire • 06/10/2024 11:15:00 AM
- La filiale d’IPA, BioStrand, annonce un LLM avancé pour les dossiers de santé électroniques • Business Wire • 06/04/2024 09:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:11:55 PM
- IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) • Business Wire • 06/04/2024 11:00:00 AM
- InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA • Business Wire • 03/28/2024 06:35:00 PM
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications • Business Wire • 03/28/2024 11:02:00 AM
- IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA • Business Wire • 03/20/2024 05:52:00 PM
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments • Business Wire • 03/20/2024 11:02:00 AM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024* • Business Wire • 03/14/2024 11:39:00 PM
- IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* • Business Wire • 03/14/2024 12:05:00 PM
- BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT • Business Wire • 03/07/2024 08:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 04:19:01 PM
- IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology • Business Wire • 03/07/2024 12:02:00 PM
- L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024 • Business Wire • 03/04/2024 09:50:00 PM
- IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 • Business Wire • 03/04/2024 01:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2024 10:29:18 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM